Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CRYSVITA vs BEYFORTUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
Treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older,Treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
16.4 days (terminal elimination half-life); supports monthly subcutaneous dosing.
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
Metabolized into small peptides and amino acids via catabolic pathways; not metabolized by cytochrome P450 enzymes.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Renal (minimal, as intact antibody); catabolized into small peptides and amino acids; no biliary/fecal elimination of intact drug.
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
Target-mediated binding to FGF23; low nonspecific binding to other plasma proteins (typical for m Abs).
Protein binding is approximately 99.5%, primarily to albumin.
3.8 L (approximately 0.05 L/kg for a 70 kg adult); indicates limited extravascular distribution (confined mainly to plasma volume).
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
Subcutaneous: ~78% relative to intravenous administration (absolute bioavailability not determined due to lack of IV formulation).
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
No dose adjustment required in renal impairment. Safety and efficacy not established in severe renal impairment (e GFR <30 m L/min/1.73 m²) or on dialysis.
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
No specific dose adjustment recommended for elderly patients (≥65 years). Use based on weight and clinical response.
Not indicated for geriatric population; no dosing recommendations available.
None.
No black box warning.
Hypersensitivity reactions including anaphylaxis,Hyperphosphatemia and risk of nephrocalcinosis/nephrolithiasis,Dental abscesses and infections,Local injection site reactions
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
Concomitant use with phosphate binders or active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol),Severe renal impairment or end-stage renal disease
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
Avoid high-phosphorus foods and beverages (e.g., dairy products, nuts, seeds, whole grains, cola, chocolate, organ meats) while on CRYSVITA, as they may increase serum phosphorus levels and risk of hyperphosphatemia. Dietary phosphate restriction is recommended. No specific food-drug interactions known; however, maintain consistent phosphorus intake between doses.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
CRYSVITA (burosumab) is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23). There are no adequate and well-controlled studies in pregnant women. In animal studies, administration of burosumab to pregnant monkeys during organogenesis resulted in no teratogenic effects at doses up to 5.9 times the human dose. However, due to the mechanism of action, potential risks include disturbances in phosphate and vitamin D metabolism which may affect fetal skeletal development. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
It is not known whether burosumab is excreted in human milk. As a monoclonal antibody, burosumab is likely to be minimally transferred into breast milk and is expected to undergo proteolytic digestion in the gastrointestinal tract. The M/P ratio is unknown. Consider the developmental and health benefits of breastfeeding along with the mother's clinical need for CRYSVITA and any potential adverse effects on the breastfed child.
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
No specific dose adjustment guidelines are established for pregnancy. The pharmacokinetics of burosumab may be altered due to pregnancy-induced physiological changes, including increased plasma volume and altered clearance. Monitor serum phosphorus levels and adjust dosing based on clinical response and tolerability. Consider dose adjustments if significant changes in serum phosphorus or adverse effects occur.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
CRYSVITA (burosumab) is a recombinant human monoclonal Ig G1 antibody to fibroblast growth factor 23 (FGF23), indicated for X-linked hypophosphatemia (XLH) in adult and pediatric patients aged 1 year and older. Administer subcutaneously every 2 weeks (pediatric: starting 0.8 mg/kg, max 1.2 mg/kg; adult: 1.0 mg/kg, max 90 mg). Monitor serum phosphorus closely, aiming for age-appropriate normal range. Do not initiate if serum phosphorus is within normal range. Concomitant use with oral phosphate and active vitamin D analogs is not recommended. May cause injection site reactions, headache, and hyperphosphatemia. Discontinue if severe hypersensitivity occurs. Pregnancy and breastfeeding: limited data; use only if clearly needed.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
CRYSVITA is given as an injection under the skin every 2 weeks. Do not miss doses.,Do not take phosphate supplements or active vitamin D (e.g., calcitriol) while on CRYSVITA unless specifically instructed by your doctor.,Report symptoms of high phosphorus levels: muscle cramps, numbness, tingling, or irregular heartbeat.,Common side effects include injection site reactions (redness, pain, swelling), headache, and back pain.,Pregnancy and breastfeeding: inform your doctor if you are pregnant, plan to become pregnant, or are nursing.,Store CRYSVITA in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Allow to reach room temperature before injecting.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CRYSVITA vs BEYFORTUS, answered by our medical review team.
CRYSVITA is a Monoclonal Antibody that works by Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.. BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CRYSVITA and BEYFORTUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CRYSVITA is: 1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.. The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CRYSVITA and BEYFORTUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CRYSVITA is classified as Category C. CRYSVITA (burosumab) is a monoclonal antibody that inhibits fibroblast growth factor 23 (FGF23). There are no adequate and well-controlled studies in pregnant women. In animal stud. BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.